Seite auswählen

Swiss biotechnology company Actelion has, in the wake of its savings programme, dismissed fewer people from its headquarters than was initially expected. Instead of the initial 70 redundancies planned by the company from Allschwil, Basel, there are now only 40 taking place.

The reason: more people than expected have opted for voluntary redundancy from the company, explained a spokesman. Worldwide, 135 of its 2,500 employees have been dismissed, mainly in research and development. Once the patent for the main revenue Tracleer – a medicine for high blood pressure in pulmonary circulation – was leaked, Actelion was forced to make cuts. It normally generated 90% of sales, equivalent to SF 1.5 million.

[ilink url=““] Link zur Quelle ([/ilink]